Eunice Wang, MD, Roswell Park Cancer Center, Buffalo, NY, emphasizes the importance of mutational profiling in patients with acute myeloid leukemia (AML) for identifying new therapeutic targets and improving prognostic predictions. She mentions that without mutational profiling, predictions about disease outcomes may be inaccurate, potentially leading to patients missing out on personalized treatment options that could improve their care. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
